Author:
Putri Denise U.,Feng Po-Hao,Lin Chiou-Feng,Haryana Sofia M.,Soesatyo Marsetyawan H. N. E.,Lee Kang-Yun,Han Chia-Li
Abstract
AbstractLocal administration of attenuated mycobacterium has been used as a cancer treatment adjuvant to re-boost patient immune responses with variable clinical outcomes. We aimed to clarify the impact of attenuated heat-killed tuberculosis (HKTB) on tumor-associated macrophages which play critical roles in shaping immunological regulation in the tumor microenvironment. Upon HKTB stimulation, both primary macrophages derived from the peripheral blood of healthy subjects and from lung cancer patients as well as THP1-derived classically activated macrophages (Ms) and tumor-educated macrophages (TEMs) were polarized into the proinflammatory phenotype, as characterized by increased expression cluster of differentiation 86. A quantitative proteomic analysis revealed that stimulated TEMs were unable to activate the toll-like receptor 2, signal transducer and activator of transcription 1, or nuclear factor-κB signaling. Instead, they showed distinct intercellular adhesion molecule 1 signaling, impaired cell adhesion, and mitochondrial dysfunction. These molecular mechanisms might contribute to lower cytotoxicity of HKTB-stimulated TEMs against A549 cells via the release of distinct inflammatory cytokines compared to HKTB-stimulated Ms. Our study provides an unbiased and systematic interpretation of cellular and molecular alterations of HKTB-reeducated macrophages which should help illuminate potential strategies of HKTB-stimulated macrophage-based combination therapy for cancer treatment.
Funder
Ministry of Science and Technology, Taiwan
Ministry of Education
Publisher
Springer Science and Business Media LLC
Reference62 articles.
1. Nauts, H. C., Fowler, G. A. & Bogatko, F. H. A review of the influence of bacterial infection and of bacterial products (Coley’s toxins) on malignant tumors in man; a critical analysis of 30 inoperable cases treated by Coley’s mixed toxins, in which diagnosis was confirmed by microscopic examination selected for special study. Acta Med. Scand. Suppl. 276, 1–103 (1953).
2. Grange, J. M., Bottasso, O., Stanford, C. A. & Stanford, J. L. The use of mycobacterial adjuvant-based agents for immunotherapy of cancer. Vaccine 26, 4984–4990. https://doi.org/10.1016/j.vaccine.2008.06.092 (2008).
3. Kaimala, S., Al-Sbiei, A., Cabral-Marques, O., Fernandez-Cabezudo, M. J. & Al-Ramadi, B. K. Attenuated bacteria as immunotherapeutic tools for cancer treatment. Front. Oncol. 8, 136. https://doi.org/10.3389/fonc.2018.00136 (2018).
4. Staedtke, V., Roberts, N. J., Bai, R. Y. & Zhou, S. Clostridium novyi-NT in cancer therapy. Genes Dis. 3, 144–152. https://doi.org/10.1016/j.gendis.2016.01.003 (2016).
5. Wood, L. M. & Paterson, Y. Attenuated Listeria monocytogenes: A powerful and versatile vector for the future of tumor immunotherapy. Front. Cell Infect. Microbiol. 4, 51. https://doi.org/10.3389/fcimb.2014.00051 (2014).